Alivus Life Sciences Ltd · NSE:ALIVUS
Alivus Life Sciences — Q3 FY25 Earnings Presentation
21 slides from Alivus Life Sciences's earnings presentation, Jan 23, 2025
Slide 1: Stock exchange filing cover letter
January 23, 2025 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322
Slide 2: Investor Presentation Q3 & 9M FY25
Investor Presentation Q3 & 9M FY25
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Financial Performance Review
Financial Performance Review 3
Slide 5: Q3FY25 Highlights
Q3FY25 | Highlights “The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. Dr. Yasir Rawjee I am pleased to report that our Q3 performance reflects this renewed energy, with Managing Director & growth across both GPL and Non-GPL segments. Geographically, re
Slide 6: Q3 & 9M FY25 Performance
Q3 & 9M FY25 Performance Revenue EBITDA PAT EPS (In ₹ Mill i on s ) (In ₹ Mill i on s ) (In ₹ Mill i on s ) (In ₹) 30.4% 31.3% 21.3% 28.2% 20.7% 11.18 6,418 26.9% 28.0% 18.9% 18.8% 18.3% 5,886 5,728 9.69 1,370 5,366 9.10 2,008 5,069 1,188 1,742 7.99 1,115 7.78 1,650 1,446 1,429 979 953 Q3 Q4 Q1 Q2 Q
Slide 7: P&L Highlights | Q3 & 9M FY25
P&L Highlights | Q3 & 9M FY25 Particulars (In ₹ Millions) Q3 FY25 Q2 FY25 QoQ Q3 FY24 YoY 9M FY25 9M FY24 YoY FY24 Revenue from Operations 6,418 5,069 26.6% 5,728 12.0% 17,373 17,466 -0.5% 22,832 Gross Profit 3,566 2,817 26.6% 3,306 7.9% 9,391 9,833 -4.5% 12,812 Gross Profit (%) 55.6% 55.6% 57.7% 54
Slide 8: Healthy Return Indicators
Healthy Return Indicators ROICE (%) Fixed Assets Turnover (Times) Working Capital Days 40% 176 170 182 166 36% 152 34% 33% 3.3 3.4 2.9 112 29% 2.7 102 107 2.5 99 89 120 116 136 122 138 -43 -53 -59 FY21 FY22 FY23 FY24 9M FY25 FY21 FY22 FY23 FY24 9M FY25 -72 -68 • ROICE is tracking at ~29% – Capital e
Slide 9: Robust Growth & Steady Profitability
Robust Growth & Steady Profitability Revenue EBITDA PAT EPS (In ₹ Mil l ions ) (In ₹ Mill i on s ) (In ₹ Mill i on s ) (In ₹) EBITDA PAT EBITDA Margin PAT Margin 21.6% 20.6% 31.5% 31.1% 20.4% 19.7% 31.4% 30.6% 30.1% 22,832 18.6% 4,709 4,670 38.4 21,612 38.1 21,232 6,863 4,187 6,712 35.6 6,308 18,852
Slide 10: Business Performance Review
Business Performance Review 9
Slide 11: Segmental Performance | Generic API vs CDMO
Segmental Performance | Generic API vs CDMO Generic API CDMO (Revenu e In ₹ Milli o n s ) (Revenu e In ₹ Milli o ns ) 425 5,966 5,354 355 354 5,105 4,846 4,739 300 240 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 • Generic API revenues in Q3FY25 grew by 25.9% • CDM
Slide 12: Segmental Performance | GPL vs Non-GPL
Segmental Performance | GPL vs Non-GPL GPL % of Total Revenue Non-GPL % of Total Revenue (In ₹ Mill i on s ) (In ₹ Mill i on s ) 33.4% 37.2% 72.4% 73.1% 31.1% 27.6% 26.9% 4,187 68.9% 4,645 1,963 1,888 66.6% 1,773 3,699 1,667 3,181 1,541 3,923 62.8% Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q3 FY24 Q4
Slide 13: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix Market Mix Therapeutic Area Mix 17% 16% 13% 18% 19% 31% 33% 33% 38% 36% 6% 4% Others 6% 3% 5% 5% 4% 3% 5% Emerging 5% Pain Management Markets 15% 14% 14% 11% 16% Diabetes 83% 84% 87% 82% 81% CNS Regulated Markets CVS 43% 41% 41% 44% 44% Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25
Slide 14: Company Overview
LIFE SCIENCES Company Overview ¢
Slide 15: Global Footprint
Global Footprint • Filed 548 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 70+ 370+ 30+ 109 143 168 10+ 19 125+ 10+ 50+ 22 87 (Brazil) India – Mix of Regulated Number of Number of customers As of December 31, Re
Slide 16: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend (In ₹ Mill i on s ) North Therapy Europe Japan Brazil Australia ROW Total America 3.3% 3.2% CVS 38 37 4 21 10 38 148 3.0% CNS 39 25 8 16 2 20 110 753 Diabetes 10 5 - 9 - 14 38 2.7% 652 Pain Management 1 2 - 4 1 9 17 Others 80 40 7 37 9 62 235 2.1%
Slide 17: Quality Focused Manufacturing and R&D Infrastructure
Quality Focused Manufacturing and R&D Infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Last USFDA Location Approvals Mahape, Navi Mumbai Capacity Inspection Date USFDA, MHRA (UK), FIMEA ▪ R&D for new product (Finland), Romania (Europe) PMDA development and complex Ankl
Slide 18: Strategy Going Forward
LIFE SCIENCES Strategy Going Forward ¢
Slide 19: Strategy Growth Levers
Strategy Growth Levers 1 Gx API Business ✓ New product launches 2 ✓ Geographical expansion New Growth levers ✓ Focus on new markets becoming more regulated ✓ CDMO Ramp up ✓ Pursue 2nd source opportunities with top generic players ✓ Expand into complex API platforms ✓ Iron compounds ✓ Oncology & HP A
Slide 20: Future Capacity Expansion
Future Capacity Expansion Operational Expansion Type Division Location Status & Planned Capacity Timelines Brownfield API / Intermediate Ankleshwar Planned addition of 60KL Pharma Capacity FY26 Brownfield API Dahej Planned addition of 160KL FY26 Phase 1 – 200 KL (Construction started) FY26 Greenfiel
Slide 21: Thank You
Thank You FOR FURTHER INFORMATION CONTACT Email: complianceofficer@alivus.com ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE RUNJHUN JAIN SNEHA SALIAN Email: Diwakar.Pingle@in.ey.com Email: Runjhun.Jain1@in.ey.com Email: sneha2.salian@in.ey.com CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68